reports

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

April 03, 2026 16:00 ET  | Source: IN8bio, Inc NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the…

2 months ago

GAC Reports Strong Q1 Overseas Growth, Led by AION V and Hong Kong Breakthrough

GUANGZHOU, China, April 3, 2026 /PRNewswire/ -- GAC continued its strong overseas momentum in March, with monthly sales of its…

2 months ago

Zoomlion Reports 2025 Results With International Revenue Approaching 60% of Total

Global reach and diversified businesses continue to support growthCHANGSHA, China, April 2, 2026 /PRNewswire/ -- Zoomlion Heavy Industry Science &…

2 months ago

Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update

– Released positive topline data from Phase 1 study of IV rademikibart in patients with asthma or COPD – –…

2 months ago

Eightco (NASDAQ: ORBS) Reports Total Holdings of $326 Million, Includes Nearly 280 Million Worldcoin and Over 11,000 ETH

ORBS offers public market exposure to the most innovative private companies including OpenAI and Beast IndustriesORBS bridges a critical gap…

2 months ago

Jiayin Group Inc. Reports Fourth Quarter and Fiscal Year 2025Unaudited Financial Results

SHANGHAI, March 31, 2026 (GLOBE NEWSWIRE) -- Jiayin Group Inc. (“Jiayin” or the “Company”) (NASDAQ: JFIN), a leading fintech platform…

2 months ago

3F’s Holding S.A. reports Consolidated Financial Statements for the 2024/2025 Financial Year

LUXEMBOURG, March 30, 2026 /PRNewswire/ -- 3F's Holding S.A. has approved its Consolidated Financial Statements for the 2024/2025 financial year, ended…

3 months ago

Huize Holding Limited Reports Unaudited Financial Results for the Second Half and Full Year 2025

SHENZHEN, China, March 27, 2026 (GLOBE NEWSWIRE) -- Huize Holding Limited, (“Huize”, the “Company” or “we”) (NASDAQ: HUIZ), a leading…

3 months ago

Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates

Product sales and commercial rights revenues in 2025 increased 90% year-over-year to US$82.1 million (RMB574.1 million)Sales of Olverembatinib increased 81% year-over-year…

3 months ago

Nexteer Reports 2025 Year End Results

Continues Above-Market Growth with Expanding MarginsAUBURN HILLS, Mich., March 24, 2026 /PRNewswire/ -- Nexteer Automotive (HK 1316) today reported financial…

3 months ago